American Family Children's Hospital
Michael S. Huie, MD close
Michael S. Huie, MD

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Michael S. Huie, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Michael S. Huie, MD, earned his medical degree from the University of Wisconsin-Madison and completed his residency at UW Hospital and Clinics. He is a member of the UW Health Breast Center.



Medical Oncology

UW Health Clinics

1 S. Park Clinic
(608) 287-2933 | (888) 703-2778 | Map
1 S. Park Clinic
(608) 287-2552 | (888) 703-2778 | Map

Regional Specialty Clinics

Monroe Clinic (Monroe)
(608) 324-2685 |  Map

Hospital Affiliation(s)

UnityPoint Health - Meriter (primary)
University Hospital (secondary)

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School University of Wisconsin - Madison, Madison, WI, 2000

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.


Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.

PubMed Articles
Hoang T Campbell TC Zhang C Kim K Kolesar JM Oettel KR Blank JH Robinson EG Ahuja HG Kirschling RJ Johnson PH Huie MS Wims ME Larson MM Hernan HR Traynor AM . Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Invest New Drugs. 2014 Feb;32(1):195-9
[PubMed ID: 23728919]
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS . VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7
[PubMed ID: 21848883]
Attia S Morgan-Meadows S Holen KD Bailey HH Eickhoff JC Schelman WR Traynor AM Mulkerin DL Campbell TC McFarland TA Huie MS Cleary JF Tevaarwerk AJ Alberti DB Wilding G Liu G . Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51
[PubMed ID: 18841362]
Traynor AM Dubey S Eickhoff JC Kolesar JM Schell K Huie MS Groteluschen DL Marcotte SM Hallahan CM Weeks HR Wilding G Espinoza-Delgado I Schiller JH . Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol. 2009 Apr;4(4):522-6
[PubMed ID: 19347984]
Huie M Oettel K Van Ummersen L Kim KM Zhang Y Staab MJ Horvath D Marnocha R Douglas J Drezen A Alberti D Wilding G . Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma. Invest New Drugs. 2006 May;24(3):255-60
[PubMed ID: 16205854]
Huie M Carducci M Liu G Wilding G Marnocha R Izquierda M Thomas J . Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors. Am J Clin Oncol. 2005 Dec;28(6):613-7
[PubMed ID: 16317274]